Skip to Content

'
David G. Menter, Ph.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Cancer Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Administrative Director, Department of Cancer Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

I am interested in the molecular and cellular biology ofgastrointestinal tumors. These studies involve four primary areas ofresearch: 1) to understand microenvironmental and age related effects ofthe colon stromal on CRC; 2) to examine the role of the stromalcell eicosanoid pathway and inflammatory pathway effects on CRC; 3) toexamine the role of mesenchymal and epithelial stem cells in thedevelopment of CRC and 4) to develop mechanism based approaches of applyingnanotechnology to cancer prevention. These studies involve isolating andcharacterizing cells from colon tumors as well as colon liver metastases. Thesecells will be used in co-culture experiments with colon tumor cells toexamine the their ability to inhibit or promote the growth of tumor cellsin vitro or in vivo. Further molecular and eicosanoid profiling will beperformed co-cultured cells to dissect out the critical changes that occurwhen these cells interact during tumor formation. In the future, As apart of the age related effects of stromal cells on CRC, in the process ofisolating normal colon and pancreatic mesenchymal and epithelial cellsfrom various age wt or APCmin mice. These mesenchymal cells will be usedin co-culture experiments with colon tumor cells to examine the effect ofage or inflammatory bioactive lipids on the ability of mesenchymal cellsto inhibit or promote the growth  of tumor cells in vitro or in vivo.

Education & Training

Degree-Granting Education

1986 Wayne State University, Detroit, MI, PHD, Cell Biology
1976 Wayne State University, Detroit, MI, BS, Biology

Postgraduate Training

1986-1992 Research Fellowship, Cell Biology, The University of Texas, Houston, TX

Experience/Service

Institutional Committee Activities

Committee Member, Animal Research Infrastructure Strategic Planning Committee, 2008-present
Member, User Committee for the Analytical Core of the UTMDACC Cancer Center Support Grant, 2005-present
Member, Institutional Animal Care and Use Committee, 1999-present

Honors and Awards

2002 HSC Honors Convocation Recipient, University of Texas Health Science Center
1998 Flemming and Davenport Award, Texas Medical Center
1997 Postdoctoral Support Award, Meadows Foundation
1997 Shannon Award, National Cancer Institute
1987 Histopathobiology of Neoplasia Workshop, National Cancer Institute
1986 National Cancer Institute Postdoctoral Fellow in Human Genetics, National Cancer Institute
1984 Outstanding Researcher Award, Sigma Xi: The Scientific Research Society

Selected Publications

Peer-Reviewed Original Research Articles

1. Menter DG, Patterson SL, Logsdon CD, Kopetz S, Sood AK, Hawk ET. Convergence of nanotechnology and cancer prevention: are we there yet? Cancer Prev Res (Phila) 7(10):973-92, 10/2014. e-Pub 7/2014. PMID: 25060262.
2. Yang P, Cartwright C, Efuet E, Hamilton SR, Wistuba II, Menter D, Addington C, Shureiqi I, Newman RA. Cellular location and expression of Na+, K+ -ATPase α subunits affect the anti-proliferative activity of oleandrin. Mol Carcinog 53(4):253-63, 4/2014. e-Pub 10/2012. PMID: 23073998.
3. Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev 33(1):231-69, 3/2014. PMCID: PMC4186918.
4. Menter DG, Dubois RN. Prostaglandins in Cancer Cell Adhesion, Migration, and Invasion. Int J Cell Biol 2012:723419, 2012. e-Pub 2/29/2012. PMCID: PMC3299390.
5. Kim SH, Xia D, Kim SW, Holla V, Menter DG, Dubois RN. Human enhancer of filamentation 1 Is a mediator of hypoxia-inducible factor-1alpha-mediated migration in colorectal carcinoma cells. Cancer Res 70(10):4054-63, 5/15/2010. e-Pub 5/4/2010. PMCID: PMC2871069.
6. Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 16(5):1384-90, 3/1/2010. e-Pub 2/23/2010. PMID: 20179228.
7. Xia D, Holla VR, Wang D, Menter DG, DuBois RN. HEF1 is a crucial mediator of the proliferative effects of prostaglandin E(2) on colon cancer cells. Cancer Res 70(2):824-31, 1/15/2010. e-Pub 1/12/2010. PMCID: PMC2943830.
8. Yang P, Menter DG, Cartwright C, Chan D, Dixon S, Suraokar M, Mendoza G, Llansa N, Newman RA. Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug targets. Mol Cancer Ther 8(8):2319-28, 8/2009. e-Pub 8/2009. PMID: 19671733.
9. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 101(5):306-20, 2009. PMCID: PMC2734116.
10. Jin Q, Menter DG, Mao L, Hong WK, Lee HY. Survivin expression in normal human bronchial epithelial cells: an early and critical step in tumorigenesis induced by tobacco exposure. Carcinogenesis 29(8):1614-22, 2008. PMID: 18635526.
11. Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia 7:280-93, 2005. PMID: 15799828.
12. Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res 65:6189-98, 2005. PMID: 16024620.
13. Sabichi AL, Subbarayan V, Llansa N, Lippman SM, Menter DG. PPARg suppresses cyclooxygenase-2 expression in human prostate cells. Cancer Epidemiol Biomarkers and Prev 13:1704-9, 2004.
14. Menter DG. Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention. Expert Opin Investig Drugs 11(12):1749-64, 12/2002. PMID: 12457435.
15. Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG. Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Res 61:2720-6, 2001. PMID: 11289153.
16. Menter, DG, Gundlach, N, Steinert, BW, Diglio, C, Walz, D, Sloane, B F, Taylor, JD, Honn, KV. Platelet enhancement of tumor cell adhesion to endothelial cell extracellular matrix. Cancer Res 47:6751-62, 1987.

Grant & Contract Support

Title: Prostaglandins and Inflammation in Colorectal Cancer
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator-MDACC
Principal Investigator: David G. Menter
Duration: 4/1/2010 - 4/1/2013
 
Title: Nuclear Hormone Receptors and Intestinal Epithelial Biology
Funding Source: NIH/NIDDK
Role: Investigator
Principal Investigator: Raymond DuBois
Duration: 7/1/2002 - 6/11/2011
 
Title: Role of Eicosanoids in Intestinal Epithelial Growth and Function
Funding Source: NIH/NIDDK
Role: Investigator
Principal Investigator: Raymond DuBois
Duration: 8/20/1994 - 7/31/2013

Last updated: 11/20/2014